Skip to main content
Carol Schermer, MD, General Surgery, Oshkosh, WI

CarolRSchermerMDMPH, FACS

General Surgery • Oshkosh, WI

Trauma Surgery & Surgical Critical Care

Intensivist-Sound Physicians

Join to view full profile

Dr. Schermer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schermer's full profile

Already have an account?

  • Office

    855 N Westhaven Dr
    Oshkosh, WI 54904
    Phone+1 920-303-8700

Education & Training

  • University of California Davis Health
    University of California Davis HealthFellowship, Surgical Critical Care, 1996 - 1997
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineResidency, Surgery, 1991 - 1996
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineClass of 1991

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - Present
  • IL State Medical License
    IL State Medical License 2006 - 2026
  • NM State Medical License
    NM State Medical License 1997 - 2025
  • WI State Medical License
    WI State Medical License 2021 - 2025
  • NC State Medical License
    NC State Medical License 2005 - 2006
  • American Board of Surgery Surgery
  • American Board of Surgery Surgical Critical Care

Awards, Honors, & Recognition

  • Fellow (FACS) American College of Surgeons

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • FDA Approves Supplemental New Drug Application for Myrbetriq® (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
    FDA Approves Supplemental New Drug Application for Myrbetriq® (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder SymptomsMay 7th, 2018
  • FDA Approves Supplemental New Drug Application for Myrbetriq (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder Symptoms
    FDA Approves Supplemental New Drug Application for Myrbetriq (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder SymptomsAugust 29th, 2011

Grant Support

  • Trauma Center Brief Alcohol Treatments And COST EffectivenesNational Institute On Alcohol Abuse And Alcoholism2006–2007
  • Prevention Of DUI Recidivism After TraumaNational Center For Research Resources2004–2007
  • Use Of Heparin For Thromboprophylaxis In TraumaNational Center For Research Resources2004–2005
  • Prevention Of DUI Recidivism After TraumaNational Institute On Alcohol Abuse And Alcoholism2000–2004

Professional Memberships

Dr. Carol Schermer, Dr. Carol Schermer, MD, Dr. C Schermer, Dr. Carol R Schermer